ClinicalTrials.gg

Stomach Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,404 studies for Stomach Neoplasms across more than 10 countries. 996 are recruiting or about to start. 2,334 of them are mainly about Stomach Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Gastro-enteropancreatic neuroendocrine tumor too: 3,473 studies, 1,016 open.

ClinicalTrials.gov finds 4,386 studies for Stomach Neoplasms. How that becomes 3,401 here

This page counts the studies the registry files under Stomach Neoplasms, and those it files under no condition that list Stomach Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 4,386Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −59Filed under a narrower condition, counted on its own pageGastro-enteropancreatic neuroendocrine tumor 57
  3. −46List Stomach Neoplasms as a condition, but the registry did not file them under itMost often written as “Clinical Stage IV Gastric Cancer AJCC v8” (11), “Clinical Stage III Gastric Cancer AJCC v8” (10), and “Advanced Gastric Cancer” (5). The registry filed them under other conditions only, most often Neoplasm Metastasis (8) and Colorectal Neoplasms (7).
  4. −880Match it another way218 name it in the title, 12 in a keyword, and 650 by a synonym or other text the search reads.
  5. 3,401The count on this page213 of them list Stomach Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
1,220
Recruiting
705
Status unknown
679
Not yet recruiting
259
Terminated
219
Active, not recruiting
208

Phase

Phase 2
1,191
Phase 1
694
Phase 3
323
Phase 4
71
Early Phase 1
41

Where

China
1,184
United States
804
Korea, Republic of
521
Japan
181
Spain
173
Germany
161

Who develops what

Add Stomach Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 117 programs from 78 companies, 49 with this as their studies’ main aim; 18 with a live phase 3 study; 18 primary completions in the next 12 months. Compare AstraZeneca, Beijing Biotech and BioNTech here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CapecitabineRecent, repeated
Evidence
  • NCT07829757 · Astellas Pharma Inc · Phase 4 · live · background · “Capecitabine” · registered Sep 2026
  • NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Capecitabine” · registered Sep 2026
  • NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Capecitabine” · registered Aug 2026
  • NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Capecitabine” · registered Feb 2026
  • NCT07431281 · AstraZeneca · Phase 3 · live · background · “Capecitabine” · registered Jan 2026
Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized1117 studies
OxaliplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07829757 · Astellas Pharma Inc · Phase 4 · live · background · “Oxaliplatin” · registered Sep 2026
  • NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Oxaliplatin” · registered Sep 2026
  • NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Oxaliplatin” · registered Aug 2026
  • NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Oxaliplatin” · registered Feb 2026
  • NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “Oxaliplatin” · registered Jan 2026
Sanofi35% of its industry studies1116 studies
NivolumabRecent, repeated
Evidence
  • NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Nivolumab” · registered Sep 2026
  • NCT07700979 · Akeso · Phase 3 · live · comparator · “Nivolumab” · registered Jul 2026
  • NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Nivolumab” · registered Feb 2026
  • NCT07392892 · Pfizer · Phase 3 · live · comparator · “Nivolumab” · registered Jan 2026
  • NCT07431281 · AstraZeneca · Phase 3 · live · background · “Nivolumab” · registered Jan 2026
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)1011 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT07332533 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Pembolizumab” · registered Dec 2025
  • NCT07315750 · RemeGen Co., Ltd. · Phase 3 · live · comparator · “Pembrolizumab” · registered Dec 2025
  • NCT06998771 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Pembolizumab” · registered May 2025
  • NCT06764875 · AstraZeneca · Phase 3 · live · comparator · “Pembrolizumab” · registered Dec 2024
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)910 studies
TrastuzumabRecent, repeated
Evidence
  • NCT07332533 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Trastuzumab” · registered Dec 2025
  • NCT07315750 · RemeGen Co., Ltd. · Phase 3 · live · background · “Trastuzumab” · registered Dec 2025
  • NCT07040059 · Dr. Reddy's Laboratories Limited · Phase 2 · comparator · “Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)” · registered Jun 2025
  • NCT06998771 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Trastuzumab” · registered May 2025
  • NCT06764875 · AstraZeneca · Phase 3 · live · comparator · “Trastuzumab” · registered Dec 2024
Hoffmann-La Roche55% of its industry studiesUS: Hoffmann-La Roche (FDA 1998) + 6 othersEU: Hoffmann-La Roche (EMA 2000) + 8 others911 studies
PaclitaxelRecent, repeated
Evidence
  • NCT07518147 · Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Apr 2026
  • NCT06346392 · AstraZeneca · Phase 3 · live · background · “Ramucirumab+ paclitaxel” · registered Feb 2024
  • NCT06123494 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan” · registered Nov 2023
  • NCT06038578 · Toray Industries, Inc · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed77 studies
FluorouracilRecent, repeated
Evidence
  • NCT07829757 · Astellas Pharma Inc · Phase 4 · live · background · “5-fluorouracil” · registered Sep 2026
  • NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Fluorouracil” · registered Sep 2026
  • NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “5-Fluorouracil” · registered Aug 2026
  • NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “5Fluorouracil” · registered Feb 2026
  • NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “5-Fluorouracil” · registered Jan 2026
Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed712 studies
IrinotecanRecent, repeated
Evidence
  • NCT07518147 · Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Irinotecan hydrochloride” · registered Apr 2026
  • NCT07364422 · Jeil Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Irinotecan (drug)” · registered Jan 2026
  • NCT06346392 · AstraZeneca · Phase 3 · live · background · “Irinotecan” · registered Feb 2024
  • NCT06219941 · AstraZeneca · Phase 2 · live · background · “Irinotecan” · registered Nov 2023
  • NCT06123494 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan” · registered Nov 2023
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)67 studies
DocetaxelRecent, repeated
Evidence
  • NCT07518147 · Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Docetaxel” · registered Apr 2026
  • NCT06947291 · CSPC Pharmaceutical Group Limited · Phase 2 · live · background · “Docetaxel for Injection (Albumin-bound)” · registered Apr 2025
  • NCT06346392 · AstraZeneca · Phase 3 · live · background · “Docetaxel” · registered Feb 2024
  • NCT06296706 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Taxotere (docetaxel)” · registered Feb 2024
  • NCT06123494 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan” · registered Nov 2023
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized57 studies
LeucovorinRecent, repeated
Evidence
  • NCT07829757 · Astellas Pharma Inc · Phase 4 · live · background · “Folinic Acid” · registered Sep 2026
  • NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Leucovorin Calcium” · registered Sep 2026
  • NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Leucovorin” · registered Feb 2026
  • NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “Leucovorin” · registered Jan 2026
  • NCT07069712 · AstraZeneca · Phase 2 · live · background · “Calcium folinate” · registered Jun 2025
Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed58 studies
CAPOX RegimenRecent, repeated
Evidence
  • NCT07700979 · Akeso · Phase 3 · live · background · “CAPOX regimen” · registered Jul 2026
  • NCT07315750 · RemeGen Co., Ltd. · Phase 3 · live · comparator · “CAPOX (oxaliplatin/capecitabine)” · registered Dec 2025
  • NCT07221149 · Bristol-Myers Squibb · Phase 3 · live · background · “Capox” · registered Oct 2025
  • NCT07040059 · Dr. Reddy's Laboratories Limited · Phase 2 · comparator · “Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)” · registered Jun 2025
  • NCT05322577 · Amgen · Phase 2 · background · “CAPOX” · registered Apr 2022
—55 studies
RamucirumabRecent, repeated
Evidence
  • NCT06346392 · AstraZeneca · Phase 3 · live · background · “Ramucirumab+ paclitaxel” · registered Feb 2024
  • NCT06123494 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan” · registered Nov 2023
  • NCT06038578 · Toray Industries, Inc · Phase 2 · live · background · “Ramucirumab” · registered Aug 2023
  • NCT05311176 · Imugene Limited · Phase 2 · background · “Ramucirumab plus Paclitaxel” · registered Mar 2022
  • NCT04704934 · Daiichi Sankyo · Phase 3 · live · comparator · “Ramucirumab” · registered Jan 2021
Eli Lilly and Company91% of its industry studiesUS: Eli Lilly and Company (FDA 2014)EU: Eli Lilly and Company (EMA 2014)44 studies
CisplatinRecent, repeated
Evidence
  • NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Cisplatin” · registered Aug 2026
  • NCT07332533 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Cisplatin” · registered Dec 2025
  • NCT06764875 · AstraZeneca · Phase 3 · live · comparator · “Cisplatin” · registered Dec 2024
  • NCT05489211 · AstraZeneca · Phase 2 · live · background · “Cisplatin” · registered Jul 2022
  • NCT05152147 · Jazz Pharmaceuticals · Phase 3 · live · background · “Cisplatin” · registered Nov 2021
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed34 studies
BevacizumabRecent, repeated
Evidence
  • NCT06730750 · Bristol-Myers Squibb · Phase 2 · live · background · “Bevacizumab” · registered Dec 2024
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2023
  • NCT05489211 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Jul 2022
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Bevacizumab” · registered Aug 2021
  • NCT03929666 · Jazz Pharmaceuticals · Phase 2 · background · “Bevacizumab” · registered Feb 2019
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others33 studies
GemcitabineRecent, repeated
Evidence
  • NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Gemcitabine” · registered Aug 2026
  • NCT06219941 · AstraZeneca · Phase 2 · live · background · “Gemcitabine” · registered Nov 2023
  • NCT05173142 · HUTCHMED · Phase 2 · background · “gemcitabine and cisplatin” · registered Oct 2021
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Gemcitabine” · registered Aug 2021
  • NCT04683939 · BioNTech SE · Phase 2 · background · “Gemcitabine” · registered Dec 2020
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed22 studies
Antineoplastic AgentsRecent, repeated
Evidence
  • NCT07392892 · Pfizer · Phase 3 · live · background · “Chemotherapy” · registered Jan 2026
  • NCT06731478 · Daiichi Sankyo · Phase 3 · live · background · “Chemotherapy” · registered Dec 2024
  • NCT05111626 · Amgen · Phase 3 · background · “Chemotherapy” · registered Oct 2021
  • NCT04868877 · Genmab · Phase 2 · background · “Chemotherapy” · registered Apr 2021
  • NCT02873520 · Ningbo Cancer Hospital · Phase 2 · background · “Chemotherapy” · registered Aug 2016
—22 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
  • NCT05489211 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Jul 2022
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Carboplatin” · registered Aug 2021
  • NCT04644068 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Oct 2020
Eli Lilly and Company16% of its industry studies22 studies
LevoleucovorinRecent, repeated
Evidence
  • NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Levoleucovorin” · registered Sep 2026
  • NCT06219941 · AstraZeneca · Phase 2 · live · background · “l-leucovorin” · registered Nov 2023
  • NCT01590719 · Hoffmann-La Roche · Phase 2 · background · “Levofolinic acid” · registered May 2012
Aurobindo Pharma100% of its industry studies22 studies
TegafurRecent, repeated
Evidence
  • NCT06256328 · Ono Pharmaceutical Co. Ltd · Phase 2 · live · background · “S-1” · registered Jan 2024
  • NCT05322577 · Amgen · Phase 2 · background · “SOX” · registered Apr 2022
  • NCT05144854 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “S-1” · registered Oct 2021
  • NCT03662659 · Bristol-Myers Squibb · Phase 2 · background · “SOX” · registered Sep 2018
  • NCT03615326 · Merck & Co., Inc · Phase 3 · background · “S-1” · registered Jul 2018
Otsuka Holdings Co., Ltd.76% of its industry studies22 studies
gimeracilRecent, repeated
Evidence
  • NCT06256328 · Ono Pharmaceutical Co. Ltd · Phase 2 · live · background · “S-1” · registered Jan 2024
  • NCT05322577 · Amgen · Phase 2 · background · “SOX” · registered Apr 2022
  • NCT05144854 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “S-1” · registered Oct 2021
  • NCT03662659 · Bristol-Myers Squibb · Phase 2 · background · “SOX” · registered Sep 2018
  • NCT03615326 · Merck & Co., Inc · Phase 3 · background · “S-1” · registered Jul 2018
Otsuka Holdings Co., Ltd.76% of its industry studies22 studies
Oxonic AcidRecent, repeated
Evidence
  • NCT06256328 · Ono Pharmaceutical Co. Ltd · Phase 2 · live · background · “S-1” · registered Jan 2024
  • NCT05322577 · Amgen · Phase 2 · background · “SOX” · registered Apr 2022
  • NCT05144854 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “S-1” · registered Oct 2021
  • NCT03662659 · Bristol-Myers Squibb · Phase 2 · background · “SOX” · registered Sep 2018
  • NCT03615326 · Merck & Co., Inc · Phase 3 · background · “S-1” · registered Jul 2018
Otsuka Holdings Co., Ltd.76% of its industry studies22 studies
aldesleukinRecent, repeated
Evidence
  • NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Aldesleukin” · registered Feb 2022
  • NCT05207722 · Celularity Incorporated · Phase 2 · background · “Recombinant Human Interleukin-2” · registered Jan 2022
  • NCT04426669 · intima bioscience inc · Phase 2 · background · “Aldesleukin” · registered Jun 2020
Chiron Corporation45% of its industry studiesUS: Chiron Corporation (FDA 1992)22 studies
avelumabRecent, repeated
Evidence
  • NCT05419362 · Genome & Company · Phase 2 · background · “Avelumab” · registered Jun 2022
  • NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Avelumab” · registered Feb 2022
  • NCT02625623 · Merck KGaA, Darmstadt, Germany · Phase 3 · comparator · “Avelumab” · registered Dec 2015
Pfizer44% of its industry studiesUS: Merck KGaA, Darmstadt, Germany (FDA 2017)EU: Merck KGaA, Darmstadt, Germany (EMA 2017)22 studies
atezolizumabRecent, repeated
Evidence
  • NCT06090318 · Rain Oncology Inc · Phase 2 · background · “Atezolizumab” · registered Nov 2022
  • NCT05253053 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Combination Product: Atezolizumab” · registered Jan 2022
  • NCT03829501 · Sanofi · Phase 2 · background · “Atezolizumab” · registered Jan 2019
Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017)22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT05678205 · Artiva Biotherapeutics, Inc. · Phase 2 · background · “Cyclophosphamide” · registered Dec 2022
  • NCT05207722 · Celularity Incorporated · Phase 2 · background · “Cyclophosphamide” · registered Jan 2022
  • NCT04426669 · intima bioscience inc · Phase 2 · background · “Cyclophosphamide” · registered Jun 2020
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT05678205 · Artiva Biotherapeutics, Inc. · Phase 2 · background · “Fludarabine” · registered Dec 2022
  • NCT05207722 · Celularity Incorporated · Phase 2 · background · “Fludarabine” · registered Jan 2022
  • NCT04426669 · intima bioscience inc · Phase 2 · background · “Fludarabine” · registered Jun 2020
Beijing Biotech18% of its industry studies22 studies

27 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
disitamab vedotin☆ Track5 live phase-3 studies: NCT07315750, NCT05980481, NCT06944496RemeGen Co., Ltd.
trastuzumab rezetecan☆ Track1 live phase-3 study: NCT06123494Jiangsu HengRui Medicine Co., Ltd.
tislelizumabApproved: US 2024 · EU 2023☆ Track1 live phase-3 study: NCT06944496RemeGen Co., Ltd.
trastuzumab deruxtecanApproved: US 2019 · EU 2021☆ Track2 live phase-3 studies: NCT06731478, NCT04704934Daiichi Sankyo
rilvegostomig☆ Track2 live phase-3 studies: NCT06764875, NCT07431281AstraZeneca

The 5 in phase 3 with the nearest primary completion, of 117 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (18)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 17 Nov 2026 est.sonesitatug vedotin · AstraZeneca · Phase 2 main aimstudied with Fluorouracilstudied with Irinotecanstudied with LeucovorinNCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 — primary endpoint: Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs. · 226 enrolled
  • Dec 2026 est.disitamab vedotin · RemeGen Co., Ltd. · Phase 3 main aimNCT06221748 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy — primary endpoint: Objective remission rate (ORR) (Phase II) · 90 enrolled
  • Dec 2026 est.TH9619 · One-carbon Therapeutics AB · Phase 2 named, not the main aimNCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors — primary endpoint: Frequency of treatment-emergent adverse events (TEAEs) · 43 enrolled

15 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Stomach Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 122 open · Tyrosine kinase inhibitors (TKIs) 48 open · Antimetabolites 27 open · Antimitotic agents 23 open · Antibody-drug conjugates (ADCs) 23 open

Coming up

290studies finish main data collection within a year16 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 705 Stomach Neoplasms studies recruiting now, 377 (53%) set no upper age limit and 194 (28%) stop at 75 or younger. 28 (4%) take children under 18. 2 (<1%) are for women only and 0 (0%) for men only; 70 (10%) take healthy volunteers.

Recruiting studies that take each age, of 705
AgeWomenMen
1025 (4%)25 (4%)
18612 (87%)610 (87%)
30680 (96%)678 (96%)
40694 (98%)692 (98%)
50698 (99%)696 (99%)
65699 (99%)697 (99%)
75659 (93%)657 (93%)
85431 (61%)429 (61%)

Across all 3,404 studies, recruiting or not: 27% stop at 75 or younger and 2% at 65; 6% take children; <1% are for women only and <1% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Stomach Neoplasms studies take

Of 360 phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 50 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 151 mo33–66 · 242 studies50 mo34–65 · 167 studies53 mo31–… · 75 studies
Phase 1/260 mo40–109 · 157 studies60 mo41–109 · 90 studies60 mo36–133 · 67 studies
Phase 250 mo31–75 · 360 studies38 mo25–68 · 65 studies57 mo33–76 · 295 studies
Phase 2/349 mo28–52 · 26 studies——
Phase 352 mo39–96 · 118 studies45 mo32–55 · 45 studies79 mo46–144 · 73 studies
Phase 412 mo11–17 · 27 studies——
Interventional, no phase36 mo17–63 · 368 studies—36 mo17–66 · 357 studies
Observational54 mo29–119 · 366 studies—57 mo29–171 · 324 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered31

Show 26 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,404. Browse all 3,404 → or search them.